SCHEMBL23987070

SCHEMBL23987070

CSC1=N/C(=C\c2ccc3nc(C)sc3c2)C(=O)N1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.56
▸ GAA P10253 1/20 0.56
▸ DYRK1A Q13627 11/20 0.54
▸ DYRK1B Q9Y463 11/20 0.54
▸ DYRK3 O43781 9/20 0.54
▸ DYRK2 Q92630 9/20 0.54
▸ PIM1 P11309 3/20 0.54
▸ CSNK2A2 P19784 3/20 0.54
▸ CSNK2B P67870 3/20 0.54
▸ CSNK2A1 P68400 3/20 0.54
▸ CSNK2A3 Q8NEV1 3/20 0.54
▸ HPGD P15428 2/20 0.53
▸ CLK1 P49759 8/20 0.48
▸ CLK4 Q9HAZ1 8/20 0.48
▸ CLK2 P49760 6/20 0.48
▸ CLK3 P49761 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.47
▸ CNR1 P21554 1/20 0.44
▸ CNR2 P34972 1/20 0.44
▸ GPR18 Q14330 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30145012 1.00 MAPT (0.56) MAPTGAADYRK1ADYRK1BDYRK3
SCHEMBL30145008 0.88 KDM4E (0.58) MAPTGAADYRK1ADYRK1BDYRK3
SCHEMBL28945547 0.88 KDM4E (0.58) MAPTGAADYRK1ADYRK1BDYRK3
SCHEMBL25590187 0.87 CLK1 (0.52) MAPTGAADYRK1ADYRK1BDYRK3
SCHEMBL30144962 0.80 CLK1 (0.60) MAPTGAADYRK1ADYRK1BDYRK3
SCHEMBL23970084 0.80 CLK1 (0.60) MAPTGAADYRK1ADYRK1BDYRK3
SCHEMBL26092928 0.77 MAPT (0.62) MAPTGAADYRK1ADYRK1BDYRK3
SCHEMBL30363453 0.77 MAPT (0.62) MAPTGAADYRK1ADYRK1BDYRK3
SCHEMBL26096202 0.76 MAPT (0.58) MAPTGAADYRK1ADYRK1BDYRK3
SCHEMBL30275506 0.76 CLK1 (0.51) MAPTGAADYRK1ADYRK1BDYRK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2023-06-01 — — US disclosed
CN-115515953-A Novel imidazolidinone derivatives as inhibitors of protein kinases, in particular DYRK1A, CLK1 and/or CLK4 珀哈制药公司 2022-12-23 — — CN disclosed
WO-2021219828-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 PERHA PHARMACEUTICALS (FR) 2021-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167104-A1 NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 CLK1, CLK2, CLK3 MAPT 326/4885GAA 4095/4885DYRK1A 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback